{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:12:24Z","timestamp":1791335544563,"version":"4.3.1"},"reference-count":22,"publisher":"American Association for Cancer Research (AACR)","issue":"14","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: The strength of the association between ductal carcinoma in situ (DCIS) and BRCA mutations has not been defined.<\/jats:p>\n               <jats:p>Experimental Design: Mutation frequency was compared in three groups: (1) a prevalent series of women with DCIS, (2) an incident series of women with DCIS, and (3) a clinic-based series of women with DCIS referred for hereditary cancer risk assessment. In groups 1 and 2, limited to Ashkenazi Jewish (AJ) cases, mutation frequency was compared with that in age-matched AJ controls with invasive breast cancer (IBC).<\/jats:p>\n               <jats:p>Results: In group 1, 3 of 62 (4.8%) women with DCIS and 15 of 130 (11.5%) controls with IBC had BRCA mutations. In group 2, 0 of 58 (0%) women with DCIS and 6 of 116 (5.2%) controls with IBC had BRCA mutations [combined odds ratios (OR) in groups 1 and 2: 3.64, 95% confidence interval (95% CI), 1.06-12.46; P = 0.04]. In group 3, deleterious mutations were identified in 10 of 79 (12.7%) probands with DCIS, similar to the frequency in IBC probands. In group 3, mutations were associated with family history of ovarian cancer (OR, 13.35; 95% CI, 2.48-71.94; P = 0.003) or early onset breast cancer (OR, 16.23; 95% CI, 1.68-157.01; P = 0.02) but not with AJ ethnicity or age at diagnosis.<\/jats:p>\n               <jats:p>Conclusions:BRCA mutations were less frequent in women with DCIS not selected for family history or age at diagnosis than in women with IBC. Nonetheless, mutations were found in a significant proportion of women with DCIS who presented for hereditary risk assessment.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-07-0146","type":"journal-article","created":{"date-parts":[[2007,7,19]],"date-time":"2007-07-19T00:27:07Z","timestamp":1184804827000},"page":"4306-4310","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["<i>BRCA<\/i> Mutations in Women with Ductal Carcinoma <i>In situ<\/i>"],"prefix":"10.1158","volume":"13","author":[{"given":"Karen Lisa","family":"Smith","sequence":"first","affiliation":[{"name":"1Medicine and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Adank","sequence":"additional","affiliation":[{"name":"3VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Kauff","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"},{"name":"2Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Lafaro","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Boyd","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"},{"name":"2Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna B.","family":"Lee","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Hudis","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Offit","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Robson","sequence":"additional","affiliation":[{"name":"1Medicine and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,7,18]]},"reference":[{"key":"2022061105340543600_B1","doi-asserted-by":"crossref","unstructured":"Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer\u20081996;77:2318\u201324.","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z"},{"key":"2022061105340543600_B2","doi-asserted-by":"crossref","unstructured":"Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med\u20081997;336:1401\u20138.","DOI":"10.1056\/NEJM199705153362001"},{"key":"2022061105340543600_B3","doi-asserted-by":"crossref","unstructured":"King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science\u20082003;302:643\u20136.","DOI":"10.1126\/science.1088759"},{"key":"2022061105340543600_B4","unstructured":"Satagopan JM, Offit K, Foulkes W, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev\u20082001;10:467\u201373."},{"key":"2022061105340543600_B5","doi-asserted-by":"crossref","unstructured":"Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst\u20081999;91:1241\u20137.","DOI":"10.1093\/jnci\/91.14.1241"},{"key":"2022061105340543600_B6","doi-asserted-by":"crossref","unstructured":"Sun CC, Lenoir G, Lynch H, Narod SA. In situ breast cancer and BRCA1. Lancet\u20081996;348:408.","DOI":"10.1016\/S0140-6736(05)65027-1"},{"key":"2022061105340543600_B7","doi-asserted-by":"crossref","unstructured":"Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet\u20081997;349:1505\u201310.","DOI":"10.1016\/S0140-6736(96)10109-4"},{"key":"2022061105340543600_B8","doi-asserted-by":"crossref","unstructured":"Jacquemler J, Eisinger F, Guinebretiere JM, Stoppa-Lyonnet D, Sobol H. Intraductal component and BRCA1-associated breast cancer. Lancet\u20081996;348:1098.","DOI":"10.1016\/S0140-6736(05)64441-8"},{"key":"2022061105340543600_B9","doi-asserted-by":"crossref","unstructured":"Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst\u20081998;90:1138\u201345.","DOI":"10.1093\/jnci\/91.1.90a"},{"key":"2022061105340543600_B10","doi-asserted-by":"crossref","unstructured":"Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol\u20082003;21:41\u20135.","DOI":"10.1200\/JCO.2003.02.137"},{"key":"2022061105340543600_B11","doi-asserted-by":"crossref","unstructured":"Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer\u20082003;97:1601\u20138.","DOI":"10.1002\/cncr.11225"},{"key":"2022061105340543600_B12","doi-asserted-by":"crossref","unstructured":"Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med\u20082004;351:427\u201337.","DOI":"10.1056\/NEJMoa031759"},{"key":"2022061105340543600_B13","doi-asserted-by":"crossref","unstructured":"Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol\u20082005;23:8469\u201376.","DOI":"10.1200\/JCO.2004.00.4960"},{"key":"2022061105340543600_B14","doi-asserted-by":"crossref","unstructured":"Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet\u20082005;365:1769\u201378.","DOI":"10.1016\/S0140-6736(05)66481-1"},{"key":"2022061105340543600_B15","doi-asserted-by":"crossref","unstructured":"Scheuer L, Kauff ND, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol\u20082002;20:1260\u20138.","DOI":"10.1200\/JCO.2002.20.5.1260"},{"key":"2022061105340543600_B16","doi-asserted-by":"crossref","unstructured":"Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA\u20082004;292:1317\u201325.","DOI":"10.1001\/jama.292.11.1317"},{"key":"2022061105340543600_B17","doi-asserted-by":"crossref","unstructured":"Claus EB, Petruzella S, Matloff E, Carter D. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA\u20082005;293:964\u20139.","DOI":"10.1001\/jama.293.8.964"},{"key":"2022061105340543600_B18","doi-asserted-by":"crossref","unstructured":"Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol\u20082002;20:1480\u201390.","DOI":"10.1200\/JCO.2002.20.6.1480"},{"key":"2022061105340543600_B19","doi-asserted-by":"crossref","unstructured":"Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol\u20082007;25:642\u20137.","DOI":"10.1200\/JCO.2005.04.0345"},{"key":"2022061105340543600_B20","doi-asserted-by":"crossref","unstructured":"Adank MA, Brogi E, Bogomolniy F, et al. Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue. Fam Cancer\u20082006;5:337\u201342.","DOI":"10.1007\/s10689-006-0003-y"},{"key":"2022061105340543600_B21","doi-asserted-by":"crossref","unstructured":"Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet\u20081999;64:963\u201370.","DOI":"10.1086\/302320"},{"key":"2022061105340543600_B22","doi-asserted-by":"crossref","unstructured":"Adem C, Jenkins RB, Capron F, Stoppa-Lyonnet D. High-risk lesions in high-risk women: a high-risk formalin-based biology! J Clin Oncol\u20082004;22:1159\u201361.","DOI":"10.1200\/JCO.2004.99.193"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/13\/14\/4306\/1970544\/4306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/13\/14\/4306\/1970544\/4306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T20:34:46Z","timestamp":1654979686000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/13\/14\/4306\/194658\/BRCA-Mutations-in-Women-with-Ductal-Carcinoma-In"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,15]]},"references-count":22,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2007,7,18]]},"published-print":{"date-parts":[[2007,7,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-07-0146","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,15]]}}}